Pharma & Healthcare

Orally Disintegrating Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken.
The global market for Orally Disintegrating Drug was estimated to be worth US$ 1957 million in 2023 and is forecast to a readjusted size of US$ 3709.6 million by 2030 with a CAGR of 9.5% during the forecast period 2024-2030
The orally disintegrating drug market is being driven by several factors. One of the primary drivers is the growing demand for convenient and patient-friendly medication delivery methods. Orally disintegrating drugs offer an advantage over traditional oral tablets as they quickly dissolve in the mouth without the need for water, making them easier to administer, particularly for individuals with swallowing difficulties, pediatric patients, and the elderly. Additionally, the increasing prevalence of chronic diseases and the need for efficient and immediate drug absorption have fueled the demand for orally disintegrating drugs. Furthermore, advancements in formulation technologies and taste-masking techniques have improved the palatability of these drugs, enhancing patient compliance. Overall, the demand for orally disintegrating drugs is driven by the need for convenience, improved patient experience, and enhanced drug delivery options in the pharmaceutical market.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Orally Disintegrating Drug, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Orally Disintegrating Drug by region & country, by Type, and by Application.
The Orally Disintegrating Drug market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Orally Disintegrating Drug.
Market Segmentation
By Company
Johnson and Johnson
GSK
Otsuka
Vartris
Teva
Pfizer
Eli Lilly and Company
Merck
Eisai
AstraZeneca
Bristol-Myers Squibb
Conquer
Segment by Type:
Anti-Psychotics Drug
Anti-Epileptics Drug
Other
Segment by Application
CNS Diseases
Gastrointestinal Diseases
CVS Diseases
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Orally Disintegrating Drug manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Orally Disintegrating Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Orally Disintegrating Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Orally Disintegrating Drug Product Introduction
1.2 Global Orally Disintegrating Drug Market Size Forecast
1.3 Orally Disintegrating Drug Market Trends & Drivers
1.3.1 Orally Disintegrating Drug Industry Trends
1.3.2 Orally Disintegrating Drug Market Drivers & Opportunity
1.3.3 Orally Disintegrating Drug Market Challenges
1.3.4 Orally Disintegrating Drug Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Orally Disintegrating Drug Players Revenue Ranking (2023)
2.2 Global Orally Disintegrating Drug Revenue by Company (2019-2024)
2.3 Key Companies Orally Disintegrating Drug Manufacturing Base Distribution and Headquarters
2.4 Key Companies Orally Disintegrating Drug Product Offered
2.5 Key Companies Time to Begin Mass Production of Orally Disintegrating Drug
2.6 Orally Disintegrating Drug Market Competitive Analysis
2.6.1 Orally Disintegrating Drug Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Orally Disintegrating Drug Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orally Disintegrating Drug as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Anti-Psychotics Drug
3.1.2 Anti-Epileptics Drug
3.1.3 Other
3.2 Global Orally Disintegrating Drug Sales Value by Type
3.2.1 Global Orally Disintegrating Drug Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Orally Disintegrating Drug Sales Value, by Type (2019-2030)
3.2.3 Global Orally Disintegrating Drug Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 CNS Diseases
4.1.2 Gastrointestinal Diseases
4.1.3 CVS Diseases
4.1.4 Other
4.2 Global Orally Disintegrating Drug Sales Value by Application
4.2.1 Global Orally Disintegrating Drug Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Orally Disintegrating Drug Sales Value, by Application (2019-2030)
4.2.3 Global Orally Disintegrating Drug Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Orally Disintegrating Drug Sales Value by Region
5.1.1 Global Orally Disintegrating Drug Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Orally Disintegrating Drug Sales Value by Region (2019-2024)
5.1.3 Global Orally Disintegrating Drug Sales Value by Region (2025-2030)
5.1.4 Global Orally Disintegrating Drug Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Orally Disintegrating Drug Sales Value, 2019-2030
5.2.2 North America Orally Disintegrating Drug Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Orally Disintegrating Drug Sales Value, 2019-2030
5.3.2 Europe Orally Disintegrating Drug Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Orally Disintegrating Drug Sales Value, 2019-2030
5.4.2 Asia Pacific Orally Disintegrating Drug Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Orally Disintegrating Drug Sales Value, 2019-2030
5.5.2 South America Orally Disintegrating Drug Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Orally Disintegrating Drug Sales Value, 2019-2030
5.6.2 Middle East & Africa Orally Disintegrating Drug Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Orally Disintegrating Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Orally Disintegrating Drug Sales Value
6.3 United States
6.3.1 United States Orally Disintegrating Drug Sales Value, 2019-2030
6.3.2 United States Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Orally Disintegrating Drug Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Orally Disintegrating Drug Sales Value, 2019-2030
6.4.2 Europe Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Orally Disintegrating Drug Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Orally Disintegrating Drug Sales Value, 2019-2030
6.5.2 China Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
6.5.3 China Orally Disintegrating Drug Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Orally Disintegrating Drug Sales Value, 2019-2030
6.6.2 Japan Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Orally Disintegrating Drug Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Orally Disintegrating Drug Sales Value, 2019-2030
6.7.2 South Korea Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Orally Disintegrating Drug Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Orally Disintegrating Drug Sales Value, 2019-2030
6.8.2 Southeast Asia Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Orally Disintegrating Drug Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Orally Disintegrating Drug Sales Value, 2019-2030
6.9.2 India Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
6.9.3 India Orally Disintegrating Drug Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Johnson and Johnson
7.1.1 Johnson and Johnson Profile
7.1.2 Johnson and Johnson Main Business
7.1.3 Johnson and Johnson Orally Disintegrating Drug Products, Services and Solutions
7.1.4 Johnson and Johnson Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.1.5 Johnson and Johnson Recent Developments
7.2 GSK
7.2.1 GSK Profile
7.2.2 GSK Main Business
7.2.3 GSK Orally Disintegrating Drug Products, Services and Solutions
7.2.4 GSK Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.2.5 GSK Recent Developments
7.3 Otsuka
7.3.1 Otsuka Profile
7.3.2 Otsuka Main Business
7.3.3 Otsuka Orally Disintegrating Drug Products, Services and Solutions
7.3.4 Otsuka Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.3.5 Vartris Recent Developments
7.4 Vartris
7.4.1 Vartris Profile
7.4.2 Vartris Main Business
7.4.3 Vartris Orally Disintegrating Drug Products, Services and Solutions
7.4.4 Vartris Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.4.5 Vartris Recent Developments
7.5 Teva
7.5.1 Teva Profile
7.5.2 Teva Main Business
7.5.3 Teva Orally Disintegrating Drug Products, Services and Solutions
7.5.4 Teva Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.5.5 Teva Recent Developments
7.6 Pfizer
7.6.1 Pfizer Profile
7.6.2 Pfizer Main Business
7.6.3 Pfizer Orally Disintegrating Drug Products, Services and Solutions
7.6.4 Pfizer Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.6.5 Pfizer Recent Developments
7.7 Eli Lilly and Company
7.7.1 Eli Lilly and Company Profile
7.7.2 Eli Lilly and Company Main Business
7.7.3 Eli Lilly and Company Orally Disintegrating Drug Products, Services and Solutions
7.7.4 Eli Lilly and Company Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.7.5 Eli Lilly and Company Recent Developments
7.8 Merck
7.8.1 Merck Profile
7.8.2 Merck Main Business
7.8.3 Merck Orally Disintegrating Drug Products, Services and Solutions
7.8.4 Merck Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.8.5 Merck Recent Developments
7.9 Eisai
7.9.1 Eisai Profile
7.9.2 Eisai Main Business
7.9.3 Eisai Orally Disintegrating Drug Products, Services and Solutions
7.9.4 Eisai Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.9.5 Eisai Recent Developments
7.10 AstraZeneca
7.10.1 AstraZeneca Profile
7.10.2 AstraZeneca Main Business
7.10.3 AstraZeneca Orally Disintegrating Drug Products, Services and Solutions
7.10.4 AstraZeneca Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.10.5 AstraZeneca Recent Developments
7.11 Bristol-Myers Squibb
7.11.1 Bristol-Myers Squibb Profile
7.11.2 Bristol-Myers Squibb Main Business
7.11.3 Bristol-Myers Squibb Orally Disintegrating Drug Products, Services and Solutions
7.11.4 Bristol-Myers Squibb Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.11.5 Bristol-Myers Squibb Recent Developments
7.12 Conquer
7.12.1 Conquer Profile
7.12.2 Conquer Main Business
7.12.3 Conquer Orally Disintegrating Drug Products, Services and Solutions
7.12.4 Conquer Orally Disintegrating Drug Revenue (US$ Million) & (2019-2024)
7.12.5 Conquer Recent Developments
8 Industry Chain Analysis
8.1 Orally Disintegrating Drug Industrial Chain
8.2 Orally Disintegrating Drug Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Orally Disintegrating Drug Sales Model
8.5.2 Sales Channel
8.5.3 Orally Disintegrating Drug Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Orally Disintegrating Drug Market Trends
Table 2. Orally Disintegrating Drug Market Drivers & Opportunity
Table 3. Orally Disintegrating Drug Market Challenges
Table 4. Orally Disintegrating Drug Market Restraints
Table 5. Global Orally Disintegrating Drug Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Orally Disintegrating Drug Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Orally Disintegrating Drug Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Orally Disintegrating Drug Product Type
Table 9. Key Companies Time to Begin Mass Production of Orally Disintegrating Drug
Table 10. Global Orally Disintegrating Drug Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orally Disintegrating Drug as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Orally Disintegrating Drug Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Orally Disintegrating Drug Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Orally Disintegrating Drug Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Orally Disintegrating Drug Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Orally Disintegrating Drug Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Orally Disintegrating Drug Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Orally Disintegrating Drug Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Orally Disintegrating Drug Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Orally Disintegrating Drug Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Orally Disintegrating Drug Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Orally Disintegrating Drug Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Orally Disintegrating Drug Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Orally Disintegrating Drug Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Orally Disintegrating Drug Sales Value by Region (2019-2024) & (%)
Table 27. Global Orally Disintegrating Drug Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Orally Disintegrating Drug Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Orally Disintegrating Drug Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Orally Disintegrating Drug Sales Value, (2025-2030) & (US$ Million)
Table 31. Johnson and Johnson Basic Information List
Table 32. Johnson and Johnson Description and Business Overview
Table 33. Johnson and Johnson Orally Disintegrating Drug Products, Services and Solutions
Table 34. Revenue (US$ Million) in Orally Disintegrating Drug Business of Johnson and Johnson (2019-2024)
Table 35. Johnson and Johnson Recent Developments
Table 36. GSK Basic Information List
Table 37. GSK Description and Business Overview
Table 38. GSK Orally Disintegrating Drug Products, Services and Solutions
Table 39. Revenue (US$ Million) in Orally Disintegrating Drug Business of GSK (2019-2024)
Table 40. GSK Recent Developments
Table 41. Otsuka Basic Information List
Table 42. Otsuka Description and Business Overview
Table 43. Otsuka Orally Disintegrating Drug Products, Services and Solutions
Table 44. Revenue (US$ Million) in Orally Disintegrating Drug Business of Otsuka (2019-2024)
Table 45. Otsuka Recent Developments
Table 46. Vartris Basic Information List
Table 47. Vartris Description and Business Overview
Table 48. Vartris Orally Disintegrating Drug Products, Services and Solutions
Table 49. Revenue (US$ Million) in Orally Disintegrating Drug Business of Vartris (2019-2024)
Table 50. Vartris Recent Developments
Table 51. Teva Basic Information List
Table 52. Teva Description and Business Overview
Table 53. Teva Orally Disintegrating Drug Products, Services and Solutions
Table 54. Revenue (US$ Million) in Orally Disintegrating Drug Business of Teva (2019-2024)
Table 55. Teva Recent Developments
Table 56. Pfizer Basic Information List
Table 57. Pfizer Description and Business Overview
Table 58. Pfizer Orally Disintegrating Drug Products, Services and Solutions
Table 59. Revenue (US$ Million) in Orally Disintegrating Drug Business of Pfizer (2019-2024)
Table 60. Pfizer Recent Developments
Table 61. Eli Lilly and Company Basic Information List
Table 62. Eli Lilly and Company Description and Business Overview
Table 63. Eli Lilly and Company Orally Disintegrating Drug Products, Services and Solutions
Table 64. Revenue (US$ Million) in Orally Disintegrating Drug Business of Eli Lilly and Company (2019-2024)
Table 65. Eli Lilly and Company Recent Developments
Table 66. Merck Basic Information List
Table 67. Merck Description and Business Overview
Table 68. Merck Orally Disintegrating Drug Products, Services and Solutions
Table 69. Revenue (US$ Million) in Orally Disintegrating Drug Business of Merck (2019-2024)
Table 70. Merck Recent Developments
Table 71. Eisai Basic Information List
Table 72. Eisai Description and Business Overview
Table 73. Eisai Orally Disintegrating Drug Products, Services and Solutions
Table 74. Revenue (US$ Million) in Orally Disintegrating Drug Business of Eisai (2019-2024)
Table 75. Eisai Recent Developments
Table 76. AstraZeneca Basic Information List
Table 77. AstraZeneca Description and Business Overview
Table 78. AstraZeneca Orally Disintegrating Drug Products, Services and Solutions
Table 79. Revenue (US$ Million) in Orally Disintegrating Drug Business of AstraZeneca (2019-2024)
Table 80. AstraZeneca Recent Developments
Table 81. Bristol-Myers Squibb Basic Information List
Table 82. Bristol-Myers Squibb Description and Business Overview
Table 83. Bristol-Myers Squibb Orally Disintegrating Drug Products, Services and Solutions
Table 84. Revenue (US$ Million) in Orally Disintegrating Drug Business of Bristol-Myers Squibb (2019-2024)
Table 85. Bristol-Myers Squibb Recent Developments
Table 86. Conquer Basic Information List
Table 87. Conquer Description and Business Overview
Table 88. Conquer Orally Disintegrating Drug Products, Services and Solutions
Table 89. Revenue (US$ Million) in Orally Disintegrating Drug Business of Conquer (2019-2024)
Table 90. Conquer Recent Developments
Table 91. Key Raw Materials Lists
Table 92. Raw Materials Key Suppliers Lists
Table 93. Orally Disintegrating Drug Downstream Customers
Table 94. Orally Disintegrating Drug Distributors List
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources
Table 98. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Orally Disintegrating Drug Product Picture
Figure 2. Global Orally Disintegrating Drug Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Orally Disintegrating Drug Sales Value (2019-2030) & (US$ Million)
Figure 4. Orally Disintegrating Drug Report Years Considered
Figure 5. Global Orally Disintegrating Drug Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Orally Disintegrating Drug Revenue in 2023
Figure 7. Orally Disintegrating Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Anti-Psychotics Drug Picture
Figure 9. Anti-Epileptics Drug Picture
Figure 10. Other Picture
Figure 11. Global Orally Disintegrating Drug Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 12. Global Orally Disintegrating Drug Sales Value Market Share by Type, 2023 & 2030
Figure 13. Product Picture of CNS Diseases
Figure 14. Product Picture of Gastrointestinal Diseases
Figure 15. Product Picture of CVS Diseases
Figure 16. Product Picture of Other
Figure 17. Global Orally Disintegrating Drug Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global Orally Disintegrating Drug Sales Value Market Share by Application, 2023 & 2030
Figure 19. North America Orally Disintegrating Drug Sales Value (2019-2030) & (US$ Million)
Figure 20. North America Orally Disintegrating Drug Sales Value by Country (%), 2023 VS 2030
Figure 21. Europe Orally Disintegrating Drug Sales Value (2019-2030) & (US$ Million)
Figure 22. Europe Orally Disintegrating Drug Sales Value by Country (%), 2023 VS 2030
Figure 23. Asia Pacific Orally Disintegrating Drug Sales Value (2019-2030) & (US$ Million)
Figure 24. Asia Pacific Orally Disintegrating Drug Sales Value by Country (%), 2023 VS 2030
Figure 25. South America Orally Disintegrating Drug Sales Value (2019-2030) & (US$ Million)
Figure 26. South America Orally Disintegrating Drug Sales Value by Country (%), 2023 VS 2030
Figure 27. Middle East & Africa Orally Disintegrating Drug Sales Value (2019-2030) & (US$ Million)
Figure 28. Middle East & Africa Orally Disintegrating Drug Sales Value by Country (%), 2023 VS 2030
Figure 29. Key Countries/Regions Orally Disintegrating Drug Sales Value (%), (2019-2030)
Figure 30. United States Orally Disintegrating Drug Sales Value, (2019-2030) & (US$ Million)
Figure 31. United States Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
Figure 32. United States Orally Disintegrating Drug Sales Value by Application (%), 2023 VS 2030
Figure 33. Europe Orally Disintegrating Drug Sales Value, (2019-2030) & (US$ Million)
Figure 34. Europe Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
Figure 35. Europe Orally Disintegrating Drug Sales Value by Application (%), 2023 VS 2030
Figure 36. China Orally Disintegrating Drug Sales Value, (2019-2030) & (US$ Million)
Figure 37. China Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
Figure 38. China Orally Disintegrating Drug Sales Value by Application (%), 2023 VS 2030
Figure 39. Japan Orally Disintegrating Drug Sales Value, (2019-2030) & (US$ Million)
Figure 40. Japan Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
Figure 41. Japan Orally Disintegrating Drug Sales Value by Application (%), 2023 VS 2030
Figure 42. South Korea Orally Disintegrating Drug Sales Value, (2019-2030) & (US$ Million)
Figure 43. South Korea Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
Figure 44. South Korea Orally Disintegrating Drug Sales Value by Application (%), 2023 VS 2030
Figure 45. Southeast Asia Orally Disintegrating Drug Sales Value, (2019-2030) & (US$ Million)
Figure 46. Southeast Asia Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
Figure 47. Southeast Asia Orally Disintegrating Drug Sales Value by Application (%), 2023 VS 2030
Figure 48. India Orally Disintegrating Drug Sales Value, (2019-2030) & (US$ Million)
Figure 49. India Orally Disintegrating Drug Sales Value by Type (%), 2023 VS 2030
Figure 50. India Orally Disintegrating Drug Sales Value by Application (%), 2023 VS 2030
Figure 51. Orally Disintegrating Drug Industrial Chain
Figure 52. Orally Disintegrating Drug Manufacturing Cost Structure
Figure 53. Channels of Distribution (Direct Sales, and Distribution)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies